Cart
sales@molnova.com
Desmethyl Erlotinib
CAS No. 183321-86-0
Desmethyl Erlotinib ( CP-473420, OSI-774 )
Catalog No. M12830 CAS No. 183321-86-0
OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 123 | In Stock |
|
| 2MG | 67 | In Stock |
|
| 5MG | 111 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 332 | In Stock |
|
| 50MG | 486 | In Stock |
|
| 100MG | 704 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDesmethyl Erlotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionOSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
-
DescriptionOSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
-
In Vitro——
-
In VivoDesmethyl Erlotinib exhibits t1/2 of 11.96±2.01 h in a pharmacokinetic study in Wistar rats.
-
SynonymsCP-473420, OSI-774
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number183321-86-0
-
Formula Weight379.41
-
Molecular FormulaC21H21N3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:83 mg/mL warmed (199.58 mM);Ethanol:<1 mg/mL;Water:<1 mg/Ml
-
SMILESCOCCOC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moyer JD, et al. Cancer Res. 1997, 57(21), 4838-4848.
molnova catalog
related products
-
Mutated EGFR-IN-1
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
-
FRAX597
FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
-
PD 089828
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
